Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Sirolimus

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 2 (1)

Trial Status

Unknown1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT06563817Phase 2UnknownPrimary

The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage

NCT01801267Not ApplicableCompletedPrimary

Third Ventriculostomy Versus Shunt for Children With Hydrocephalus

Showing all 2 trials

Research Network

Common Treatments

  • Sirolimus1
  • Ventricular Shunt1
  • Endoscopic Third Ventriculostomy Etv1

Active Sponsors

  • Children's Miracle Network Hospitals1
  • Beijing Tiantan Hospital1
  • Pediatric Hydrocephalus Foundation1
  • Duke University1

Top Investigators

Related Conditions

  • Post Hemorrhagic Hydrocephalus1
  • Secondary Normal Pressure Hydrocephalus1
  • Cerebral Intraventricular Hemorrhage1

Activity Timeline